In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …

The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation
(HSCT) on adults with intermediate-or high-risk acute myeloid leukemia (AML) in the first …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Approximately one-third of patients with an indication for hematopoietic cell transplantation
(HCT) have an HLA-matched related donor (MRD) available to them. For the remaining …

Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …

Progress in the last decade has improved the understanding of leukemia biology. Molecular
markers in combinations with cytogenetics have improved the risk stratification of acute …

We compared the outcomes of unrelated donor (URD, n= 358) with human leukocyte
antigen (HLA)–matched sibling donor (MSD, n= 226) transplantations in patients with acute …

Abstract Disease Overview: Acute myeloid leukemia (AML) results from accumulation of
abnormal immature cells in the marrow. These cells interfere with normal hematopoiesis can …

The yearly incidence of acute myeloblastic leukaemia (AML) in European adults is five to
eight cases per 100 000 individuals with a steep increase in the population aged over 70 …